Ross to Launch First Protein Hydrolysate Infant Formula Containing Martek's
Oils


COLUMBIA, Md., June 2 /PRNewswire/ -- Martek Biosciences Corporation (Nasdaq:<A HREF="aol://4785:MATK">
MATK</A>) announced today that Abbott Laboratories' Ross Products Division will
launch the first and only protein hydrolysate infant formula with iron in the
U.S. to be supplemented with docosahexaenoic acid (DHA) and arachidonic acid
(ARA). The United States Food and Drug Administration (FDA) has completed its
review of Ross' Alimentum(R) Advance(R), a product that will contain a blend of
Martek's DHA and ARA.  The formula is expected to be available in stores in a
ready-to-feed form beginning this summer.

Martek's oils contain the long-chain polyunsaturated fatty acids (LCPUFAs),
DHA and ARA, both of which are found in mother's breast-milk. Clinical studies
have demonstrated numerous benefits for those infants receiving DHA and
ARA-supplemented formula.  Martek's proprietary blend of DHA and ARA is the only
source of these nutrients that the FDA has cleared for use in infant formula.

"Martek strongly supports the expansion of DHA and ARA-supplemented infant
formula lines to accommodate all infants with special dietary needs," said Henry
"Pete" Linsert, Jr., Chairman and CEO of Martek Biosciences Corporation.
"This new hypoallergenic formula will provide the significant benefits of DHA and
ARA to infants with severe food allergies or colic due to protein
sensitivity."

Martek Biosciences Corporation develops, manufactures and sells products from
microalgae. The Company's products include: (1) specialty, nutritional oils
for infant formula that aid in the development of the eyes and central nervous
system in newborns; (2) nutritional supplements and food ingredients that may
play a beneficial role in promoting mental and cardiovascular health
throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid
miniaturized screening, and gene and protein detection.

This press release contains forward-looking statements regarding the
commercialization of Martek's products. Such statements involve risks and
uncertainties that could cause future actual results to differ due to a variety of risk
factors, including without limitation those factors set forth in Martek's
filings with the Securities and Exchange Commission.

Contact: Pete Buzy

Chief Financial Officer

(410) 740-0081

SOURCE  Martek Biosciences Corporation

CO:  Martek Biosciences Corporation

ST:  Maryland

SU:  PDT

Web site:  http://www.martekbio.com

http://www.prnewswire.com

06/02/2003 08:31 EDT

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html